The Cannabinoid Receptors

The Cannabinoid Receptors-1

Patricia H. Reggio Editor 2009 The identification of the cannabinoid CB1 receptor as the mediator of shortterm and a mediator of long-term retrograde inhibition of synaptic transmission has changed the cannabinoid field profoundly. For with this discovery, the CB1 receptor moved from a G-protein-coupled receptor (GPCR) associated predominantly with the drug abuse field, into the neuroscience mainstream.

Continue reading →

The Business of Bioscience

The Business of Bioscience-1

Craig D. Shimasaki 2009 What Goes into Making a Biotechnology Product My journey into this fascinating field of biotechnology started about 26 years ago at a small biotechnology company in South San Francisco called Genentech. I was very fortunate to work for the company that begat the biotech industry during its formative years. This experience established a solid […]

Continue reading →

Textbook of Personalized Medicine

Textbook of Personalized Medicine-1

Kewal K. Jain 2009 Personalized medicine, which simply means selection of treatment best suited for an individual, involves integration and translation of several new technologies in clinical care of patients. The scope is much broader than indicated by the term genomic medicine, because many non-genomic factors are taken into consideration in developing personalized medicine. Basic technologies for personalized medicine, of […]

Continue reading →

Telomeres and Telomerase in Cancer

Telomeres and Telomerase in Cancer-1

Keiko Hiyama Editor 2009 Telomerase, an enzyme that elongates telomeres and endows eukaryotic cells with immortality, was first discovered in Tetrahymena in 1985 and studied among basic scientists in the 1980s. In the 1990s, it was proven that this enzyme also plays a key role in the development of human cancers and many clinical researchers became involved in this […]

Continue reading →

Targeted Cancer Immune Therapy

Targeted Cancer Immune Therapy-1

Joseph Lustgarten • Yan Cui • Shulin Li Editors 2009 Stimulation of the immune system’s ability to control and destroy tumors continues to be the goal of cancer immune therapy; but the scope has rapidly expanded; approaches are constantly updated; new molecules are continually introduced; and immune mechanisms are becoming better understood. This book has no intention of covering […]

Continue reading →

Stem Cells and Cancer

Stem Cells and Cancer-1

Edited by REBECCA G. BAGLEY BEVERLY A. TEICHER 2009 The recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies, and cancer. Stem cell therapy is a promising approach to the treatment of many debilitating diseases to replace specific differentiated cells that have been lost or died. Although stem […]

Continue reading →

Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy

Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy-1

Andrea Bonetti • Roberto Leone Franco M. Muggia • Stephen B. Howell Editors 2009 Molecular Mechanisms and Clinical Applications Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a […]

Continue reading →

Pharming

Pharming-1

E. Rehbinder . M. Engelhard . K. Hagen . R. B. Jørgensen . R. Pardo-Avellaneda . A. Schnieke . F. Thiele 2009 Promises and risks of biopharmaceuticals derived from genetically modified plants and animals The Europäische Akademie deals with the scientific study of the consequences of scientific and technological advances for individuals and society, as well as […]

Continue reading →

Oral Delivery of Macromolecular Drugs

Oral Delivery of Macromolecular Drugs-1

Andreas Bernkop-Schnürch Editor 2009 Barriers, Strategies and Future Trends Due to a rapid development in biotechnology more and more macromolecular drugs such as therapeutic peptides, oligosaccharides and nucleic acids are entering the pharmaceutical arena representing unprecedented challenges from the drug delivery point of view. One of the likely greatest challenges is their oral administration presenting a series of attractive […]

Continue reading →

Opiate Receptors and Antagonists

Opiate Receptors and Antagonists-1

Reginald L. Dean III · Edward J. Bilsky S. Stevens Negus Editors 2009 From Bench to Clinic The evolution in our understanding of opioid receptors and their subtypes is intimately linked to the development of new pharmacological treatments for diseases/ disorders as diverse as addiction, self-injurious behavior, pain, cancer, inflammation, eating disorders, traumatic injury, pruritis, and movement disorders.

Continue reading →